ライフサイエンスコーパス: radiotherapy

1 ving initial treatment (69 after RP, 1 after radiotherapy).

2 y (control) to 95% at 10 years with adjuvant radiotherapy.

3 with no evidence of disease after surgery or radiotherapy.

4 compared with hypofractionated whole breast radiotherapy.

5 t radiotherapy was superior to early salvage radiotherapy.

6 gue within 7 days of completing whole-breast radiotherapy.

7 lvage radiotherapy and 697 (50%) to adjuvant radiotherapy.

8 ameliorate the cognitive sequelae of proton radiotherapy.

9 e of tumour cell-autonomous signalling after radiotherapy.

10 es a new strategy to improve the efficacy of radiotherapy.

11 ent survival and poor response to chemo- and radiotherapy.

12 to track response of tumors to fractionated radiotherapy.

13 Women aged 20 years with a history of chest radiotherapy.

14 luding active surveillance, prostatectomy or radiotherapy.

15 l benefit of adjuvant chemoradiotherapy over radiotherapy.

16 amethasone, and the safe omission of cranial radiotherapy.

17 ividual patient and maximize the efficacy of radiotherapy.

18 lar vesicles shed from tumor cells-following radiotherapy.

19 eting properties for application in targeted radiotherapy.

20 mors may benefit most from PD-1 blockade and radiotherapy.

21 ed to undergo unnecessary radical surgery or radiotherapy.

22 ed to eliminate resistant cancer cells in BC radiotherapy.

23 le treatments, including surgery, drugs, and radiotherapy.

24 ay be sufficient for segmental ablation with radiotherapy.

25 ence to conclude that IORT is superior to no radiotherapy.

26 herapy and provide a new strategy to enhance radiotherapy.

27 as the preferred approach for staging before radiotherapy.

28 cantly increased in CAFs secretome following radiotherapy.

29 y (CT)-density changes in the lung following radiotherapy.

30 l in patients with lung cancer, treated with radiotherapy.

31 biological research, diagnostic imaging, and radiotherapy.

32 ients treated with concomitant cisplatin and radiotherapy.

33 djusted on the basis of timing of surgery or radiotherapy.

34 sease with CMB/LCA was not improved by local radiotherapy.

35 ciated with the treatment of chemotherapy or radiotherapy.

36 P) inhibitors, especially when combined with radiotherapy.

37 loited by combining DDR inhibitors, ICIs and radiotherapy.

38 radiotherapy (7.0% vs. 5.2%), external beam radiotherapy (1.4% vs. 1.3%), enucleation (0.9% vs. 0.4%

39 went repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery).

40 survival and local control after HDT, local radiotherapy (21 Gy), and immunotherapy.

41 cal prostatectomy (RP) (79/187 had secondary radiotherapy), 30 had undergone primary radiotherapy, an

42 weeks) versus hypofractionated whole breast radiotherapy (42.5 Gy in 16 fractions over 3.5 weeks).

43 no boost following conventional whole breast radiotherapy (50 Gy in 25 fractions over 5 weeks) versus

44 The treatment groups were surgery alone, radiotherapy (55.8 Gy), chemoradiotherapy (chemotherapy

45 upillary thermotherapy (0% vs. 0.4%), plaque radiotherapy (7.0% vs. 5.2%), external beam radiotherapy

46 To reduce adverse effects of proton radiotherapy, a model of cognitive deficits from convent

47 re of PDAC cells with conditioned media from radiotherapy-activated CAFs increased iNOS/NO signaling

48 tudies showed that, although undetectable in radiotherapy-activated tumor cells, iNOS expression and

49 resection during induction chemotherapy and radiotherapy after last SCT.

50 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breas

51 t support routine administration of adjuvant radiotherapy after radical prostatectomy.

52 chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endomet

53 randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial C

54 Treatment consisted of radiotherapy alone, chemotherapy alone, or combined-moda

55 atients (75%) received CRT and 142 (25%) had radiotherapy alone.

56 (neurosurgery, embolisation, or stereotactic radiotherapy, alone or in any combination, sequence, or

57 were randomly assigned, 699 (50%) to salvage radiotherapy and 697 (50%) to adjuvant radiotherapy.

58 entially systemic immunological responses to radiotherapy and ablative therapies in patients with met

59 Potentiating radiotherapy and chemotherapy by inhibiting DNA damage r

60 er (NK) cell-based cancer immunotherapy with radiotherapy and chemotherapy in a single system.

61 a multidisciplinary treatment with surgery, radiotherapy and chemotherapy.

62 tively, invading cancer cells thus withstand radiotherapy and DNA damage by beta1/alphaVbeta3/beta5 i

63 s for selecting fractionated regimens during radiotherapy and for developing strategies to alleviate

64 py and suggest a therapeutic synergy between radiotherapy and immune checkpoint inhibitors.

65 that is highly resistant to chemotherapy and radiotherapy and is associated with poor prognosis in ad

66 it offers the opportunity to spare many men radiotherapy and its associated side-effects.

67 e high FFP, despite receiving less extensive radiotherapy and lower rates of additional androgen depr

68 metry protocols for VHEE radiotherapy, FLASH radiotherapy and other high dose-rate modalities.

69 f LGP2 in promoting antitumor immunity after radiotherapy and provide a new strategy to enhance radio

70 ry tumour with the established modalities of radiotherapy and radical prostatectomy has been explored

71 mor immune surveillance state in response to radiotherapy and suggest a therapeutic synergy between r

72 p had surgery, and 119 (89%) patients in the radiotherapy and surgery group had both radiotherapy and

73 armamentarium has expanded from whole-brain radiotherapy and surgery to include stereotactic radiosu

74 the radiotherapy and surgery group had both radiotherapy and surgery.

75 f the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering curr

76 t on limitations and opportunities in tumour radiotherapy and tissue engineering.

77 maximal safe tumour de-bulking, followed by radiotherapy and treatment with the alkylating agent Tem

78 chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemot

79 dary radiotherapy), 30 had undergone primary radiotherapy, and 70 had a persistent PSA elevation afte

80 al cancer would receive appropriate surgery, radiotherapy, and chemotherapy by 2023, which would incr

81 lopment in patients previously treated using radiotherapy, and in individuals exposed as a result of

82 cs pertinent to chemotherapy, immunotherapy, radiotherapy, and photodynamic, sonodynamic, chemodynami

83 ability of treatment (chemotherapy, surgery, radiotherapy, and targeted therapy) and imaging modaliti

84 ancer care, alongside surgery, chemotherapy, radiotherapy, and targeted therapy.

85 of patients with breast cancer who received radiotherapy, and the presence of DC correlates with gen

86 In situ immunomodulation with Flt3L, radiotherapy, and TLR3/CD40 stimulation induces an influ

87 of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as

88 Although this binary radiotherapy approach has been known for decades, BNCT f

89 sed controlled trials (RCTs) comparing these radiotherapy approaches.

90 py on CAFs and the response of PDAC cells to radiotherapy are unknown.

91 carcinoma (MEC) are treated with surgery and radiotherapy, as current systemic therapies are largely

92 oma in situ (DCIS) were randomly assigned to radiotherapy at a dose of either 50 Gy in 25 fr or 40 Gy

93 ody image than hypofractionated whole breast radiotherapy at the end of treatment (difference -1.10 [

94 ed with chemoradiotherapy and extended-field radiotherapy between 2006 and 2016 were included.

95 apy and 45 Gy radiotherapy, then surgery and radiotherapy boost based on margins with continued chemo

96 Systemic therapies and radiotherapy boost did not increase the risk of indurati

97 CCS treated with radiotherapy, busulfan, or lomustine should be closely m

98 lant sarcomas are cured by PD-1 blockade and radiotherapy, but identical treatment fails in autochtho

99 may be the result of natural remission or of radiotherapy, but the changes are of marginal clinical s

100 system for 30-day mortality after palliative radiotherapy by using predictors from routine electronic

101 compared with hypofractionated whole breast radiotherapy, by use of generalised estimating equation

102 a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiob

103 er, emerging clinical evidence suggests that radiotherapy can be incorporated into multimodality ther

104 Radiotherapy can kill cancer cells while simultaneously

105 Proton radiotherapy causes less off-target effects than X-rays

106 n-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring hospitals) in the

107 adenocarcinoma (PDAC) is highly resistant to radiotherapy, chemotherapy, or a combination of these mo

108 in vitro cell cultures or for external-beam radiotherapy clinical studies.

109 rising after completion of any postoperative radiotherapy), clinical or radiological progression, ini

110 Radiotherapy combined with chemotherapy is the major tre

111 ent-free survival was improved with adjuvant radiotherapy compared with early salvage radiotherapy (H

112 other PROs between conventional whole breast radiotherapy compared with hypofractionated whole breast

113 with no boost, and conventional whole breast radiotherapy compared with hypofractionated whole breast

114 detect an improvement from 90% with salvage radiotherapy (control) to 95% at 10 years with adjuvant

115 d of relapse of lung cancer after definitive radiotherapy (conventional fractionated radiotherapy [cR

116 est that combination of PARP inhibitors with radiotherapy could be an effective treatment option for

117 tive radiotherapy (conventional fractionated radiotherapy [cRT] or stereotactic body radiotherapy [SB

118 enefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for w

119 ire data from 2,965 CCS with clinical, chemo/radiotherapy data from medical records.

120 ritical component of treatment regardless of radiotherapy delivery method until randomized evidence d

121 Local radiotherapy did not improve survival in patients with C

122 iew and meta-analysis suggests that adjuvant radiotherapy does not improve event-free survival in men

123 substantial differences existed according to radiotherapy dose fractionation.

124 a brachytherapy boost (BT) to external beam radiotherapy (EBRT) have been shown to improve various o

125 Six cell lines were exposed to external-beam radiotherapy (EBRT) or (177)Lu-DOTATATE, after which the

126 erated hydroxyl radicals, which enhanced the radiotherapy effect.

127 treatment, and at 6, 12, and 24 months after radiotherapy: fatigue and physical functioning (EORTC QL

128 ent of standard dosimetry protocols for VHEE radiotherapy, FLASH radiotherapy and other high dose-rat

129 receive either surgery alone or preoperative radiotherapy followed by surgery.

130 enously on days 1-2) with 45 Gy preoperative radiotherapy, followed by surgical resection at week 13.

131 is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more app

132 cules in combination with adjuvant chemo- or radiotherapy following surgical resection has been propo

133 e adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (ag

134 es of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- o

135 iven the poor results using hypofractionated radiotherapy for early breast cancer, a dose of 50 Gy in

136 ngs are applicable to the strategy of immuno-radiotherapy for generating optimal antitumor immune res

137 used for more than 85 years, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not bee

138 f salivary glands is a common side effect of radiotherapy for head and neck cancer and is difficult t

139 Diagnosing relapse after radiotherapy for lung cancer is challenging.

140 herapy or an observation policy with salvage radiotherapy for PSA biochemical progression (PSA >=0.1

141 An observation policy with salvage radiotherapy for PSA biochemical progression should be t

142 like for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not establis

143 l risk traditionally associated with cranial radiotherapy for the treatment of pediatric brain tumors

144 tic cancer receiving first course palliative radiotherapy from 1 July, 2007 to 31 December, 2017 were

145 py group versus 92% for those in the salvage radiotherapy group (HR 0.88, 95% CI 0.58-1.33; p=0.53).

146 erapy group and 88% for those in the salvage radiotherapy group (HR 1.10, 95% CI 0.81-1.49; p=0.56).

147 as worse at 1 year for those in the adjuvant radiotherapy group (mean score 4.8 vs 4.0; p=0.0023).

148 radiotherapy group versus 4% in the salvage radiotherapy group (p=0.020).

149 e survival was 85% for those in the adjuvant radiotherapy group and 88% for those in the salvage radi

150 49 (93%) of 697 participants in the adjuvant radiotherapy group reported radiotherapy within 6 months

151 in 6 months; 228 (33%) of 699 in the salvage radiotherapy group reported radiotherapy within 8 years

152 eported in 6% of individuals in the adjuvant radiotherapy group versus 4% in the salvage radiotherapy

153 at 5 years was 93% for those in the adjuvant radiotherapy group versus 92% for those in the salvage r

154 ng surgery and traditional chemotherapy with radiotherapy, has contributed to improvements in overall

155 ion of tumors as a monotherapy or to improve radiotherapy have failed because oxygenation protocols w

156 Among people receiving only radiotherapy, however, the hazard for death was 17% lowe

157 ant radiotherapy compared with early salvage radiotherapy (HR 0.95, 95% CI 0.75-1.21; p=0.70), with o

158 sults: Sixty-three patients who had received radiotherapy in 70 HDVs (34 cRT; 36 SBRT) were included.

159 Radiotherapy in combination with androgen deprivation th

160 d LOY could represent an important marker of radiotherapy in NSCLC.

161 ed therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) sinc

162 topic PDAC biological models, we showed that radiotherapy increased inducible nitric oxide synthase (

163 Radiotherapy increased the risk of diabetes but not inci

164 Adjuvant radiotherapy increases the risk of urinary morbidity.

165 orescence, oxygen probe Oxyphor PtG4 and the radiotherapy-induced Cherenkov light to excite and image

166 y and for developing strategies to alleviate radiotherapy-induced toxicity to healthy tissues.

167 Clinically-relevant radiotherapy induces aberrant complement activation, lea

168 Radiotherapy induces immune-related responses in cancer

169 mains insufficient for use of intraoperative radiotherapy (IORT) in women with early stage breast can

170 Radiotherapy is a critical component of many current, cu

171 MRI-guided radiotherapy is a novel and rapidly evolving technology

172 Rationale: When stereotactic ablative radiotherapy is an option for patients with non-small ce

173 tients with NSCLC when stereotactic ablative radiotherapy is an option.

174 Thus, radiotherapy is becoming a key component of multimodal t

175 Radiotherapy is commonly used to treat a variety of soli

176 standing acute toxicities after whole-breast radiotherapy is important to inform patients, guide trea

177 he role of routine adjuvant chemotherapy and radiotherapy is not clearly established, but adjuvant th

178 plasmacytomas are highly radiosensitive and radiotherapy is therefore used as a treatment.

179 High dose-rate radiotherapy, known as FLASH, has been shown to increase

180 ction of the primary tumour and/or localised radiotherapy (locoregional therapy; LRT) could be associ

181 nt anthracycline dose of 1-99 mg/m(2) and/or radiotherapy < 15 Gy], moderate [100 to < 250 mg/m(2) or

182 rvivors treated with CED >=4,000 mg/m(2) and radiotherapy <40 Gray (P = 0.012).

183 We aimed to test whether radiotherapy may act synergistically with anti-PD-1 ther

184 esponse (DDR) inhibitors in combination with radiotherapy may be used to augment this approach.

185 (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months(1,2).

186 ow these platforms might change the roles of radiotherapy medical professionals.

187 te cancer, suggesting that multifractionated radiotherapy might be a favorable option for radio-oncol

188 ulloblastoma protocols that differed only in radiotherapy modality (PRT v XRT).

189 lude the possible complications derived from radiotherapy (mucosal necrosis, osteoradionecrosis, vasc

190 ith plaque radiotherapy (n = 3), proton beam radiotherapy (n = 1), external beam radiotherapy (n = 1)

191 ton beam radiotherapy (n = 1), external beam radiotherapy (n = 1), systemic chemotherapy (n = 4), and

192 ment failed were managed further with plaque radiotherapy (n = 3), proton beam radiotherapy (n = 1),

193 For all patients in ANBL0532 receiving radiotherapy (n = 323), 5-year CILP, EFS, and OS rates w

194 = .0088) for all patients in A3973 receiving radiotherapy (n = 328), respectively.

195 ients in A3973 with incomplete resection and radiotherapy (n = 47) were 10.6% +/- 4.6%, 48.9% +/- 10.

196 or assigned to single SCT and received boost radiotherapy (n = 74) were 16.3% +/- 4.3% (P = .4126), 5

197 iously treated or progressing after previous radiotherapy, no neurological symptoms or corticosteroid

198 tion-induced toxicities after eye-preserving radiotherapy of choroidal melanomas.

199 MRI-guided radiotherapy offers a new tool for the radiation oncolog

200 are abundant in PDAC tumors, the effects of radiotherapy on CAFs and the response of PDAC cells to r

201 referentially augment the effect of targeted radiotherapy on human orthotopic lung tumors without inf

202 ts of cancer include drugs, chemotherapy and radiotherapy or a combination.

203 randomly assigned in a 1:1 ratio to adjuvant radiotherapy or an observation policy with salvage radio

204 alignant conditions possibly associated with radiotherapy or chemotherapy (n = 13) caused the death i

205 d boost, following conventional whole breast radiotherapy or hypofractionated whole breast radiothera

206 Expanding availability of surgery or radiotherapy or improving quality of care would yield th

207 C and blocking iNOS/NO signaling may improve radiotherapy outcomes.

208 erties of yttrium, and its role in drugs for radiotherapy, PET imaging agents and perspectives for ap

209 largely been superseded by various forms of radiotherapy, phototherapy and local tumour resection, o

210 Radiotherapy planning datasets and follow-up chest CTs w

211 al approximation of NTCP could help optimise radiotherapy planning, for example by estimating the pro

212 ival has changed in relation to the trial of radiotherapy plus concomitant and adjuvant temozolomide

213 5 years (95% CI 3.9 to not estimable) in the radiotherapy plus surgery group and 5.0 years (3.4 to no

214 One (1%) of 127 patients in the radiotherapy plus surgery group died due to treatment-re

215 lymphopenia (98 [77%] of 127 patients in the radiotherapy plus surgery group vs one [1%] of 128 patie

216 y was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdomi

217 Proton radiotherapy (PRT) may lessen the neuropsychological ris

218 f relevance to the fields of cancer therapy (radiotherapy), public health (biodosimetry) and space tr

219 dentify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week tha

220 s (nMOFs) are excellent radiosensitizers for radiotherapy-radiodynamic therapy (RT-RDT).

221 overexpressing cancers to current chemo- and radiotherapy regimens.

222 omas, uterine leiomyosarcoma, melanomas, and radiotherapy-related central nervous system tumors, whic

223 Although radiotherapy remodels myeloid cells in both models, only

224 onal chemotherapy, anti-CD20 antibodies, and radiotherapy represent active treatment modalities.

225 erve as a novel target for chemotherapy- and radiotherapy-resistant breast cancer.

226 e developed a hybrid nanovesicle to stratify radiotherapy response by activatable inflammation magnet

227 RAD51AP1 KD improved chemotherapy and radiotherapy response by inhibiting BCSC self-renewal an

228 COASY is a novel radiotherapy response modulator in rectal cancer that re

229 BM) includes surgical resection and adjuvant radiotherapy (RT) and chemotherapy.

230 Although the efficacy of cancer radiotherapy (RT) can be enhanced by targeted immunother

231 e neurocognitive sequelae following clinical radiotherapy (RT) for central nervous system (CNS) malig

232 and toxicity of single dose palliative liver radiotherapy (RT) for symptomatic HCC patients.

233 ng of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa).

234 Patients undergoing outpatient radiotherapy (RT) or chemoradiation (CRT) frequently req

235 ver, the type of primary therapy and role of radiotherapy (RT) remains ill-defined.

236 ses of chemotherapy and body region-specific radiotherapy (RT) were abstracted from medical records.

237 Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT

238 aring treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus conc

239 The iodine then absorbs X-rays during radiotherapy (RT), creating free radicals and local tumo

240 metastases amenable to stereotactic ablative radiotherapy (SABR).

241 However, stereotactic body radiotherapy (SBRT) dose is often heterogeneous, making

242 PVTT downstaging (DS) with stereotactic body radiotherapy (SBRT), and tumor ablation (with transarter

243 emoembolization (TACE) and stereotactic body radiotherapy (SBRT), with an index symptom of pain or ab

244 ncer patients treated with stereotactic body radiotherapy (SBRT).

245 ated radiotherapy [cRT] or stereotactic body radiotherapy [SBRT]) were included.

246 nt irradiation dosing regimens could improve radiotherapy selection for the individual patient and ma

247 ring or skin-sparing mastectomy with planned radiotherapy should be addressed by prospective cohort s

248 Preoperative radiotherapy should not be considered as standard of car

249 in men with BCR after RP undergoing salvage radiotherapy (sRT).

250 Preclinical studies indicate that radiotherapy synergizes with immunotherapy, promoting ra

251 In patients with BCR (after prostatectomy or radiotherapy), the capacity of (18)F-JK-PSMA-7 PET/CT to

252 nt chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost based

253 effects on cancer tumors after chemotherapy/radiotherapy therapies without complicated and expensive

254 city of resected tumors treated in situ with radiotherapy, there has been little investigation of rad

255 In this Review, we describe how radiotherapy, through its immunomodulating effects, repr

256 Hazard ratios (HRs) for the effects of radiotherapy timing on event-free survival and subgroup

257 alth issue facing patients following cranial radiotherapy to control central nervous system cancers.

258 Boost radiotherapy to gross residual tumor present at the end

259 S/NO signaling plays in the effectiveness of radiotherapy to treat PDAC tumors.

260 MRI diffusion data of control and radiotherapy-treated tumours further show high sensitivi

261 rgical techniques and their reconstructions, radiotherapy treatment and chemotherapeutic guidelines.

262 further explored to combine the chemotherapy/radiotherapy treatment to enhance the therapeutic effect

263 hods: We treated 6 patients in the metabolic radiotherapy unit after thyroid stimulation.

264 Two hemodialysis sessions in the metabolic radiotherapy unit were performed at 42 and 90 h after ra

265 therapy, hormonal therapy, targeted therapy, radiotherapy use within the past 4 weeks.

266 Molecular radiotherapy using (177)Lu-DOTATATE is a most effective

267 Peptide receptor radiotherapy using (177)Lu-labeled somatostatin ligand a

268 adiotherapy or hypofractionated whole breast radiotherapy using one of three randomisation categories

269 ntially to multifractionated and single-dose radiotherapy, using a combination of genetics-based and

270 distributions in tumors during fractionated radiotherapy, using oxygen-dependent quenching of phosph

271 lower in patients after CSI (mean IQ, 90 [no radiotherapy], v 74 [CSI]; P = .012).

272 if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, followin

273 -positive lesions outside a standard salvage radiotherapy volume in 39.4% of all patients.

274 etected inside or outside a standard salvage radiotherapy volume.

275 Conventional whole breast radiotherapy was associated with worse body image than h

276 lts: Clonogenic survival after external-beam radiotherapy was cell-line-specific, indicating varying

277 After 2006, local radiotherapy was introduced for nonresponders or patient

278 sufficient power to assess whether adjuvant radiotherapy was superior to early salvage radiotherapy.

279 ed radiation is routinely used during cancer radiotherapy, we decided to delineate the effects of rad

280 ing an experimental design free of chemo- or radiotherapy, we found CD40 activation with agonistic an

281 temic cytarabine, and central nervous system radiotherapy were not used.

282 iction of the therapeutic outcomes in cancer radiotherapy, which may contribute to the future of prec

283 fective way to boost the killing efficacy of radiotherapy while drastically limiting the received dos

284 h a clinical complete response after (chemo) radiotherapy who undergo a W&W policy will experience a

285 ore abundant in leukemia patients undergoing radiotherapy, who also displayed milder gastrointestinal

286 l sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and ha

287 Targeted radiotherapy with (131)I-mIBG, a substrate of the human

288 Combining radiotherapy with beta1 or alphaV integrin monotargeting

289 After biopsy or resection and completion of radiotherapy with concomitant TMZ, 41 newly diagnosed an

290 rrent and future applications for MRI-guided radiotherapy with respect to metastatic and primary live

291 ned to category A: conventional whole breast radiotherapy with tumour bed boost (n=100) or no boost (

292 to category C: hypofractionated whole breast radiotherapy with tumour bed boost (n=182) or no boost (

293 ned to category B: conventional whole breast radiotherapy with tumour bed boost (n=223) or no boost (

294 (n=98), or to hypofractionated whole breast radiotherapy with tumour bed boost (n=98) or no boost (n

295 in the adjuvant radiotherapy group reported radiotherapy within 6 months; 228 (33%) of 699 in the sa

296 9 in the salvage radiotherapy group reported radiotherapy within 8 years after randomisation.

297 d the full planned treatment dose (70 Gy) of radiotherapy without any delays >= 5 days; 88.1% of pati

298 individual treatment modalities, scaling up radiotherapy would yield the largest absolute percentage

299 ubicin, cyclophosphamide, and etoposide plus radiotherapy) would improve patient outcomes.

300 o normal tissue compared with that of photon radiotherapy (XRT).